Voltar
Entrada de Referência Acesso aberto Revisado por pares
BIBTEX RIS

Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data

2008; Cochrane; Linguagem: Inglês

10.1002/14651858.cd007303

ISSN

1469-493X

Autores

Julia Bohlius, Sven Trelle, Olaf Weingart, Guido Schwarzer, Corinne Brillant, Mike Clarke, Benjamin Djulbegović, Margret Piper, Dirk Rades, Jerome Seidenfeld, Mark R. Somerfield, David P. Steensma, Martin Schumacher, Andreas Engert, Matthias Egger,

Tópico(s)

Artificial Intelligence in Healthcare and Education

Resumo

BackgroundErythropoiesis-stimulating agents (ESAs) reduce anemia in cancer patients and may improve quality of life, but there are concerns that ESAs might increase mortality. ObjectivesOur objectives were to examine the effect of ESAs and identify factors that modify the effects of ESAs on overall survival, progression free survival, thromboembolic and cardiovascular events as well as need for transfusions and other important safety and efficacy outcomes in cancer patients. Search strategyWe searched the Cochrane Library, Medline, Embase and conference proceedings for eligible trials.Manufacturers of ESAs were contacted to identify additional trials. Selection criteria1 Erythropoietin or Darbepoetin for patients with cancer -meta-analysis based on individual patient data (Review) Copyright © 2009 The Cochrane Collaboration.Published by

Referência(s)